Francisco Folgar, MD
Ophthalmology · Mount Pleasant, SCNPI 1801060454
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 57.6% of the total. Reporting peaked in 2023 at $13,001 and has fallen 92.4% since, to $982 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $303.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$20K
- AbbVie$6K
- Regeneron$3K
- Novartis$2K
- Genentech, Inc.$489
- Astellas Pharma US Inc$445
- plus $2K from 18 others
Across 407 payments — averaging $628.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$214K
- Roche TCRC, Inc.$28K
- Notal Vision, Inc.$14K
What the payments were for
- Consulting fees$8,13023%
- Speaking & faculty fees$20,89560%
- Travel & lodging$1,6845%
- Food & beverage$4,15812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 18 | $20,090 |
| AbbVie(2 entities) | 20 | $5,623 |
| Regeneron | 1 | $3,475 |
| Novartis | 10 | $2,396 |
| Genentech, Inc. | 2 | $489 |
| Astellas Pharma US Inc | 8 | $445 |
| Alcon | 8 | $403 |
| Notal Vision, Inc. | 7 | $348 |
| Harrow Eye, LLC | 5 | $330 |
| Genentech USA, Inc. | 9 | $327 |
| Dutch Ophthalmic, USA | 1 | $174 |
| Regeneron Healthcare Solutions, Inc. | 6 | $143 |
| Eyepoint US, Inc. | 2 | $130 |
| Aerie Pharmaceuticals, Inc. | 1 | $112 |
| Alimera Sciences, Inc. | 5 | $106 |
| Bausch & Lomb Americas Inc. | 3 | $73 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Coherus Oncology, Inc. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Biogen | 1 | $27 |
| Omeros Corporation | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Dompe US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$18,370
- OZURDEX$5,121
- EYLEA$3,475
- BEOVU$2,098
- Non-Covered Product$489
- Izervay$277
- TRIESENCE$228
- EVA, combined machine$174
- TISSUEBLUE$174
- Unity$148
- VABYSMO$141
- Constellation$124
- YUTIQ$113
- Rhopressa$112
- Rocklatan$112
How this compares
$34,867 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 196 | $10,216 |
| Lotemax SmLoteprednol Etabonate | 18 | $4,581 |
| Atropine Sulfate | 123 | $3,206 |
| Brimonidine Tartrate | 52 | $1,532 |
| Ketorolac Tromethamine | 36 | $1,527 |
| Bromfenac Sodium | 12 | $1,425 |
| Ciprofloxacin Hcl | 112 | $1,107 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 61 | $967 |
| Latanoprost | 68 | $669 |
| Acetazolamide | 12 | $440 |
| Dorzolamide Hcl | 14 | $155 |
| Timolol Maleate | 24 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $36 | $4,58118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Mount Pleasant
- Michael DecourceyMount Pleasant$14K
- Charlene GriceMount Pleasant$7K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.